Document is current

Article History

Accepted: 6 November 2023

First Online: 11 December 2023

Declarations

:

: Not applicable.

: Christian Vestergaard has acted as a speaker and/or consultant for Almirall, Sanofi A/S, Eli Lilly Denmark A/S, Novartis Healthcare A/S, Janssen-Cilag A/S, LEO Pharma A/S, AstraZeneca A/S, Eli Lilly & Co Ltd. Catalina Skovsgaard has no conflicts of interest. Claus Johansen has acted as an advisor for LEO Pharma. Mette Deleuran has received research support, honoraria for lecturing, and/or consulting/advisory board agreements from AbbVie, Eli Lilly, LEO Pharma, Arena Pharmaceuticals, ASLAN, Incyte, La Roche Posay, NUMAB Therapeutics AG, Pierre Fabre, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. Jacob P. Thyssen has been an investigator, speaker, and/or consultant for Almirall S.A., AbbVie A/S, Galderma Nordic AB, Pfizer ApS, Pfizer Ltd., LEO Pharma A/S, Sanofi-Aventis Denmark A/S, Sanofi A/S, Genzyme Europe B.V., Eli Lilly Denmark A/S. After completion of this manuscript, Jacob Thyssen has been employed at LEO Pharma, Denmark.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: CV: writing and conceptualizing, CS: writing and conceptualizing, CJ: conceptualizing and reviewing the manuscript, MD: conceptualizing and reviewing the manuscript, JT: conceptualizing and reviewing the manuscript. All authors read and approved the final manuscript.